糖尿病合并结核分枝杆菌潜伏感染的研究进展

doi:10.19871/j.cnki.xfcrbzz.2023.04.017

摘要/Abstract

摘要： 糖尿病和结核病是两种严重危害人类健康的慢性疾病,两者之间相互影响。糖尿病不仅增加了患者感染结核病的风险,还加重了结核病的严重程度和治疗难度。全球范围内,糖尿病和结核病的共患率正在上升,给公共卫生带来了巨大的挑战。目前,关于糖尿病合并结核分枝杆菌潜伏感染的流行病学资料还很缺乏,但有证据表明,糖尿病患者的结核分枝杆菌潜伏感染患病率是非糖尿病人群的两倍。为了有效地控制糖尿病合并结核分枝杆菌双重流行,需要对糖尿病合并结核分枝杆菌潜伏感染的患者进行及时的筛查、诊断和预防性治疗。本文综述了近年来关于糖尿病合并结核分枝杆菌潜伏感染的流行病学特征、相互作用、诊断方法以及预防策略等方面的最新进展,旨在为临床实践和公共卫生干预提供参考和启示。

关键词: 糖尿病, 分枝杆菌, 结核分枝杆菌潜伏感染, 药物相互作用, 预防性治疗

Abstract: Diabetes and tuberculosis are two chronic diseases that pose serious risks to human health, and there is a complex interaction between them. Diabetes not only increases the risk of tuberculosis infection, but also aggravates the severity of tuberculosis and the difficulty of treatment. The comorbidity of diabetes and tuberculosis is increasing worldwide and represents a major public health challenge. Although epidemiologic data on latent tuberculosis infection with diabetes are scarce, evidence suggests that the prevalence of latent tuberculosis infection is twice as high with diabetes as in those without diabetes. To effectively control this dual epidemic, timely screening, diagnosis and preventive treatment of patients with diabetes and latent tuberculosis infection are needed. This article reviews recent advances in the epidemiologic characteristics, interactions, diagnostic methods, and prevention strategies of latent tuberculosis infection with diabetes to provide reference and enlightenment for clinical practice and public health intervention.

Key words: Diabetes, Latent tuberculosis infection, Medicine interactions, Preventive therapy

中图分类号:

刘桂珍, 韩婷婷, 陈秋奇, 邓国防. 糖尿病合并结核分枝杆菌潜伏感染的研究进展[J]. 新发传染病电子杂志, 2023, 8(4): 85-89.

Liu Guizhen, Han Tingting, Chen Qiuqi, Deng Guofang. Research progress of diabetes mellitus with latent tuberculosis infection[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(4): 85-89.

参考文献

[1] HUANG HL, HUANG WC, LIN KD, et al.Completion Rate and Safety of Programmatic Screening and Treatment for Latent Tuberculosis Infection in Elderly Patients With Poorly Controlled Diabetic Mellitus: A Prospective Multicenter Study[J]. Clin Infect Dis, 2021, 73(6): e1252-e1260.
[2] NJIE GJ, MORRIS SB, WOODRUFF RY, et al.Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis[J]. Am J Prev Med, 2018, 55(2): 244-252.
[3] CHANG A, WU CZ, LIN JD, et al.Prevalence and risk factors for latent tuberculosis among diabetes patients in Taiwan: A cross-sectional study[J]. J Infect Dev Ctries, 2022, 16(4): 644-649.
[4] GAO L, BAI L, LIU J, et al.Annual risk of tuberculosis infection in rural China: a population-based prospective study[J]. Eur Respir J, 2016, 48(1): 168-178.
[5] HOUBEN RM, DODD PJ.The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling[J]. PLoS Med, 2016, 13(10): e1002152.
[6] 桂静, 杨慧, 傅钰, 等. 血糖血脂异常对肺结核合并2型糖尿病的影响分析[J/CD]. 新发传染病电子杂志, 2022, 7(4): 37-41.
[7] 杨松, 严晓峰. 结核病与糖尿病:相互关系和诊治的研究新进展[J/CD]. 新发传染病电子杂志, 2018, 3(4): 234-238.
[8] AL-RIFAI RH, PEARSON F, CRITCHLEY JA, et al.Association between diabetes mellitus and active tuberculosis: A systematic review and meta-analysis[J]. PLoS One, 2017, 12(11): e0187967.
[9] BAGHAEI P, MARJANI M, JAVANMARD P, et al.Diabetes mellitus and tuberculosis facts and controversies[J]. J Diabetes Metab Disord, 2013, 12(1): 58.
[10] PING PA, ZAKARIA R, ISLAM MA, et al.World Health Organization. Framework for collaborative action on tuberculosis and comorbidities[J]. J Infect Dev Ctries, 2022, 87(1):25-31.
[11] MAGEE MJ, KHAKHARIA A, GANDHI NR, et al.Increased Risk of Incident Diabetes Among Individuals With Latent Tuberculosis Infection[J]. Diabetes Care, 2022, 45(4): 880-887.
[12] BARRON MM, SHAW KM, BULLARD KM, et al.Diabetes is associated with increased prevalence of latent tuberculosis infection: Findings from the National Health and Nutrition Examination Survey, 2011-2012[J]. Diabetes Res Clin Pract, 2018, 139: 366-379.
[13] MARTINEZ-AGUILAR G, SERRANO CJ, CASTANEDA-DELGADO JE, et al.Associated Risk Factors for Latent Tuberculosis Infection in Subjects with Diabetes[J]. Arch Med Res, 2015, 46(3): 221-227.
[14] LIN CH, KUO SC, HSIEH MC, et al.Effect of diabetes mellitus on risk of latent TB infection in a high TB incidence area: a community-based study in Taiwan[J]. BMJ Open, 2019, 9(10): e029948.
[15] ODONE A, HOUBEN RM, WHITE RG, et al.The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets[J]. Lancet Diabetes Endocrinol, 2014, 2(9): 754-764.
[16] VINEY K, CAVANAUGH J, KIENENE T, et al.Tuberculosis and diabetes mellitus in the Republic of Kiribati: a case-control study[J]. Trop Med Int Health, 2015, 20(5):650-657.
[17] AYELIGN B, NEGASH M, GENETU M, et al.Immunological Impacts of Diabetes on the Susceptibility of Mycobacterium tuberculosis[J]. J Immunol Res, 2019, 2019: 6196532.
[18] MARTINEZ N, KORNFELD H.Diabetes and immunity to tuberculosis[J]. Eur J Immunol, 2014, 44(3): 617-626.
[19] RESTREPO BI, SCHLESINGER LS. Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus[J]. Tuberculosis (Edinb), 2013, Suppl(0): S10-S14.
[20] LIU Q, YAN W, LIU R, et al.The Association Between Diabetes Mellitus and the Risk of Latent Tuberculosis Infection: A Systematic Review and Meta-Analysis[J]. Front Med (Lausanne), 2022, 9: 899821.
[21] LEE MR, HUANG YP, KUO YT, et al.Diabetes Mellitus and Latent Tuberculosis Infection: A Systematic Review and Metaanalysis[J]. Clin Infect Dis, 2017, 64(6): 719-727.
[22] TEPEKULE B, KUSEJKO K, ZEEB M, et al.Impact of Latent Tuberculosis on Diabetes[J]. J Infect Dis, 2022, 225(12): 2229-2234.
[23] RONALD LA, CAMPBELL JR, ROSE C, et al.Estimated Impact of World Health Organization Latent Tuberculosis Screening Guidelines in a Region With a Low Tuberculosis Incidence: Retrospective Cohort Study[J]. Clin Infect Dis, 2019, 69(12): 2101-2108.
[24] LIN Y, HARRIES AD, KUMAR AMV, et al.Tackling diabetes mellitus and tuberculosis: a new Union guide on the management of diabetes-tuberculosis[J]. Int J Tuberc Lung Dis, 2019, 23(7): 771-772.
[25] 李相威, 金奇, 高磊. 我国结核分枝杆菌潜伏感染流行现状[J/CD]. 新发传染病电子杂志, 2017, 2(3): 146-150.
[26] MAZUREK GH, JEREB J, VERNON A, et al.Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection-United States, 2010[J]. MMWR Recomm Rep, 2010, 59(RR-5): 1-25.
[27] 中国防痨协会, 中国防痨协会学校与儿童结核病防治专业分会, 《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识[J]. 中国防痨杂志, 2020, 42(8): 761-768.
[28] LARGEN A, AYALA A, KHURANA R, et al.Evaluation of point-of-care algorithms to detect diabetes during screening for latent TB infection[J]. Int J Tuberc Lung Dis, 2021, 25(7): 547-553.
[29] SINGHAL A, JIE L, KUMAR P, et al. Metformin as adjunct antituberculosis therapy[J]. Sci Transl Med, 2014, 6(263): 263ra159.
[30] MAGEE MJ, SALINDRI AD, KORNFELD H, et al.Reduced prevalence of latent tuberculosis infection in diabetes patients using metformin and statins[J]. Eur Respir J, 2019, 53(3):1801695.
[31] SU VY, SU WJ, YEN YF, et al.Statin Use Is Associated With a Lower Risk of TB[J]. Chest, 2017, 152(3): 598-606.
[32] PADMAPRIYADARSINI C, BHAVANI PK, NATRAJAN M, et al.Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial[J]. BMJ Open, 2019, 9(3): e024363.
[33] TSENG CH.Metformin Decreases Risk of Tuberculosis Infection in Type 2 Diabetes Patients[J]. J Clin Med, 2018, 7(9):264.
[34] LEE MC, CHIANG CY, LEE CH, et al.Metformin use is associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal renal function: A nationwide cohort study with validated diagnostic criteria[J]. PLoS One, 2018, 13(10): e0205807.
[35] LIN SY, TU HP, LU PL, et al.Metformin is associated with a lower risk of active tuberculosis in patients with type 2 diabetes[J]. Respirology, 2018, 23(11): 1063-1073.
[36] VASHISHT R, BRAHMACHARI SK.Metformin as a potential combination therapy with existing front-line antibiotics for Tuberculosis[J]. J Transl Med, 2015, 13: 83.
[37] LACHMANDAS E, ECKOLD C, BOHME J, et al.Metformin Alters Human Host Responses to Mycobacterium tuberculosis in Healthy Subjects[J]. J Infect Dis, 2019, 220(1): 139-150.
[38] 谭运彩, 袁媛, 杨双喜, 等. 二甲双胍与2型糖尿病患者肺结核感染风险的倾向性评分匹配分析[J/CD]. 新发传染病电子杂志, 2021, 6(3): 202-205.
[39] 徐新月, 赵晓龙. 结核病与糖尿病共病的药物治疗进展[J/CD]. 新发传染病电子杂志, 2023, 8(2): 74-77.
[40] MEREGILDO-RODRIGUEZ ED, CHUNGA-CHEVEZ EV, GIANMARCO RL, et al.Further insights into to the role of statins against active tuberculosis: systematic review and meta-analysis[J]. Infez Med, 2022, 30(2): 194-203.
[41] TSAI IF, KUO CP, LIN AB, et al.Potential effect of ezetimibe against Mycobacterium tuberculosis infection in type II diabetes[J]. Respirology, 2017, 22(3): 559-566.
[42] HUYNH KK, GERSHENZON E, GRINSTEIN S.Cholesterol accumulation by macrophages impairs phagosome maturation[J]. J Biol Chem, 2008, 283(51): 35745-35755.
[43] YAMAMURA T, OHSAKI Y, SUZUKI M, et al.Inhibition of Niemann-Pick-type C1-like1 by ezetimibe activates autophagy in human hepatocytes and reduces mutant alpha1-antitrypsin Z deposition[J]. Hepatology, 2014, 59(4): 1591-1599.
[44] LEE PH, LIN HC, HUANG AS, et al.Diabetes and risk of tuberculosis relapse: nationwide nested case-control study[J]. PLoS One, 2014, 9(3): e92623.
[45] 杨敏, 付亮, 邓国防. 结核病并发糖尿病治疗管理相关进展[J]. 中国防痨杂志, 2021, 43(1): 87-90.
[46] SUREKHA V, PETER JV, JEYASEELAN L, et al.Drug interaction: rifampicin and glibenclamide[J]. Natl Med J India, 1997, 10(1): 11-12.
[47] JAAKKOLA T, BACKMAN JT, NEUVONEN M, et al.Effect of rifampicin on the pharmacokinetics of pioglitazone[J]. Br J Clin Pharmacol, 2006, 61(1): 70-78.
[48] NIEMI M, KIVISTO KT, BACKMAN JT, et al.Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride[J]. Br J Clin Pharmacol, 2000, 50(6): 591-595.
[49] 张霞, 汤泓. 上海市长宁区老年糖尿病患者结核潜伏感染现况和预防性治疗态度[J]. 中国热带医学, 2021, 21(5): 408-412.
[50] 艾静文, 阮巧玲, 张文宏. 结核分枝杆菌潜伏感染预防性治疗的进展[J]. 中国防痨杂志, 2015, 37(1): 80-85.
[51] JUNG YEG, SCHLUGER NW.Advances in the diagnosis and treatment of latent tuberculosis infection[J]. Curr Opin Infect Dis, 2020, 33(2): 166-172.
[52] 中国防痨协会. 高危人群结核分枝杆菌潜伏感染检测及预防性治疗专家共识[J]. 中国防痨杂志, 2021, 43(9): 874-878.